-ASTRAZENECA https://clinicaltrials.gov/ct2/show/NCT04516746

Phase 3 ends February 2023

Results published at link

Serious adverse events Injected: 140. Placebo: 78.

Medically attended adverse events Injected: 1617. Placebo: 815.

Special interest AEs Injected: 525. Placebo: 416.

Other non-serious AEs Injected: 6835. Placebo: 2206

-PFIZER/BIONTECH https://clinicaltrials.gov/ct2/show/study/NCT04368728

Phase 3 ends 31 January 2023

No results published yet

Of special note: Pregnant women excluded

-MODERNA https://clinicaltrials.gov/ct2/show/NCT04470427

Phase 3 ended 29 December 2022

No results published yet

Of special note: Pregnant women excluded

-ASTRAZENECA https://clinicaltrials.gov/ct2/show/NCT04516746

Phase 3 ends February 2023 Results published at link

Serious adverse events Injected: 140. Placebo: 78.

Medically attended adverse events Injected: 1617. Placebo: 815.

Special interest AEs Injected: 525. Placebo: 416.

Other non-serious AEs Injected: 6835. Placebo: 2206

-PFIZER/BIONTECH https://clinicaltrials.gov/ct2/show/study/NCT04368728

Phase 3 ends 31 January 2023

Of special note: Pregnant women excluded

-MODERNA https://clinicaltrials.gov/ct2/show/NCT04470427

Phase 3 ended 29 December 2022 No results published yet

Of special note: Pregnant women excluded

-AstraZeneca https://clinicaltrials.gov/ct2/show/NCT04516746

Phase 3 ends February 2023 Results published at link

Serious adverse events Injected: 140. Placebo: 78.

Medically attended adverse events Injected: 1617. Placebo: 815.

Special interest AEs Injected: 525. Placebo: 416.

Other non-serious AEs Injected: 6835. Placebo: 2206

-Pfizer / BioNTech https://clinicaltrials.gov/ct2/show/study/NCT04368728

Phase 3 ends 31 January 2023

Of special note: Pregnant women excluded

-Moderna https://clinicaltrials.gov/ct2/show/NCT04470427

Phase 3 ended 29 December 2022 No results published yet

Of special note: Pregnant women excluded